Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase <scp>II</scp> clinical trial-Reference-Cited by-同舟云学术

Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial

Published:2022-12 Issue:8 Volume:152 Page:1648-1658
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Jin Shuiling¹,Zhao Ruihua¹,Zhou Chuang²,Zhong Qian¹,Shi Jianxiang³,Su Chang¹,Li Qinglong⁴,Su Xiaoxing⁵,Chi Huabin⁵,Lu Xu²,Jiang Guozhong⁶^ORCID,Chen Renyin⁶,Han Jinming¹,Jiang Miao¹,Qiao Shishi²,Liu Jingjing⁷,Song Min¹,Song Lijie¹,Du Yabing¹,Chang Zhiwei¹,Wang Meng⁴,Dong Meilian⁸,Zhong Yali¹,Yu Pu¹,Zhang Xiaojian⁹,Zong Hong¹^ORCID

Affiliation:

1. Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

2. Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou China

3. BGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science Zhengzhou University Zhengzhou China

4. Department of Radiology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

5. Bioinformatics, Berry Oncology Co. Ltd Fujian China

6. Department of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

7. Department of MR Imaging The First Affiliated Hospital of Zhengzhou University Zhengzhou China

8. Department of Radiotherapy The First Affiliated Hospital of Zhengzhou University Zhengzhou China

9. Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Funder

Wu Jieping Medical Foundation

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34372

Reference51 articles.

1. Biliary tract cancer

2. Burden of liver diseases in the world

3. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers

4. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

5. Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis;Frontiers in Immunology;2024-08-14

2. Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study;Cancer Immunology, Immunotherapy;2024-08-06

3. Combination anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report;Anti-Cancer Drugs;2024-05-10

4. Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer;Cancer Science;2024-04-18

5. Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report;OncoTargets and Therapy;2024-04